Drug Profile
KUR 213
Alternative Names: KUR-213Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Kuros Biosurgery
- Developer Kuros Biosciences
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Wounds
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Wounds in Switzerland (Gel)